A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer (NCT07226427)
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group — Springdale, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Highlands Oncology Group — Springdale, Arkansas
- Yale University — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute — Sarasota, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Mayo Clinic — Rochester, Minnesota
- NEXT Virginia — Fairfax, Virginia
- Icon Cancer Centre — South Brisbane, Queensland
- Cancer Research SA — Aberfoyle Park,
- Hospital Universitario Dexeus - Grupo Quironsalud — Barcelona,
- Clínica Universidad Navarra — Madrid,
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Universitario HM Sanchinarro — Madrid,
- Clínica Universidad de Navarra — Pamplona,
- Hospital Quironsalud Madrid — Pozuelo de Alarcón,
📞 Contact the Study Coordinator
Phone: (877) 332-7961
Email: cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Platinum-resistant Ovarian Cancer
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) — Phoenix, Arizona
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Anchorage, Alaska
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — Little Rock, Arkansas
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — El Segundo, California
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer — Boston, Massachusetts
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — Mobile, Alabama
Explore by condition: All Platinum-resistant Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.